IP Library Granted Patent US 10,561,728
Granted Patent B2
US 10,561,728 · App. 15/991,432 · Granted Feb 18, 2020

Polynucleotides encoding anti-CD40 antibodies

Inventors: Keith A. Reimann (Marblehead, MA); Rijian Wang (Saugus, MA); Christian P. Larsen (Atlanta, GA)
Assignees: Beth Israel Deaconess Medical Center, Inc.; Emory University
A61K39/3955A61K31/436A61K38/13A61K39/39541A61K45/06A61P37/06C07K16/18C07K16/2866C07K16/2875C07K16/2878A61K2039/505A61K2039/507C07K2317/24C07K2317/33C07K2317/76Y02A50/386Y02A50/41Y02A50/412Y02A50/414Y02A50/423
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,561,728
App. No.
15/991,432
Granted
Feb 18, 2020
Kind
B2
Abstract

The present invention relates to antibodies specific for a particular epitope on CD40 and antibodies that bind CD40 and have particular functional characteristics. The present invention also relates to fragments of these antibodies, uses of the antibodies for reduction or treatment of transplant rejection and graft-versus-host disease, and methods for making the antibodies.

Claims (17)

1. A polynucleotide encoding an antibody or antigen-binding fragment thereof that specifically binds to an epitope present on CD40, wherein the heavy chain variable region of the antibody or antigen-binding fragment thereof comprises the hypervariable regions set forth in amino acids 20-132 of SEQ ID NO:2, and the light chain variable region of the antibody or antigen-binding fragment thereof comprises the hypervariable regions set forth in amino acids 23-128 of SEQ ID NO:4.

2. The polynucleotide of claim 1 , wherein the epitope is present within the sequence of amino acids 8-60 of SEQ ID NO:6.

3. The polynucleotide of claim 1 , wherein the antibody or antigen-binding fragment thereof blocks B lymphocyte activation by CD154-expressing Jurkat cells in vitro.

4. The polynucleotide of claim 1 , wherein the antibody or antigen-binding fragment thereof inhibits B lymphocyte CD23, CD80, or CD86 expression.

5. The polynucleotide of claim 3 , wherein the B lymphocyte is a rhesus B lymphocyte.

6. The polynucleotide of claim 1 , wherein the CD40 is rhesus CD40 or human CD40.

7. The polynucleotide of claim 1 , wherein the constant regions of the antibody are human constant regions.

8. The polynucleotide of claim 1 , wherein the antibody is a humanized antibody or a human antibody.

9. The polynucleotide of claim 1 , wherein the antibody is a monoclonal antibody.

10. The polynucleotide of claim 1 , wherein the heavy chain variable region of the antibody or antigen-binding fragment thereof comprises amino acids 20-132 of SEQ ID NO:2, and the light chain variable region of the antibody or antigen-binding fragment thereof comprises amino acids 23-128 of SEQ ID NO:4.

11. The polynucleotide of claim 1 , wherein the antigen-binding fragment is an antibody that lacks an Fc portion.

12. The polynucleotide of claim 1 , wherein the antigen-binding fragment is a F(ab′) 2 , a Fab, an Fv, or an scFv.

13. A vector encoding the polynucleotide of claim 1 .

14. A cell comprising the vector of claim 13 .

15. The cell of claim 13 , wherein said cell is eukaryotic.

16. The cell of claim 14 , wherein said cell is mammalian.

17. The cell of claim 13 , wherein said cell is prokaryotic.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 3, 2018
From: REIMANN, KEITH A.; WANG, RIJIAN
To: BETH ISRAEL DEACONESS MEDICAL CENTER, INC.
Reel/Frame 047052/0090 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 3, 2018
From: LARSEN, CHRISTIAN P.
To: EMORY UNIVERSITY
Reel/Frame 047052/0231 →
CONFIRMATORY LICENSE Recorded Jun 8, 2018
From: BETH ISRAEL DEACONESS MEDICAL CENTER
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 046327/0329 →
Continuity (3)
Division 14004552
Provisional Application 61451870 · Mar 11, 2011
Related Publication 20180344845A1 · Dec 6, 2018
Cited By (3)
US 12,234,294 US 12,514,924 US 12,715,929